Literature DB >> 12183414

CBFA2T3 (MTG16) is a putative breast tumor suppressor gene from the breast cancer loss of heterozygosity region at 16q24.3.

Marina Kochetkova1, Olivia L D McKenzie, Anthony J Bais, Julie M Martin, Genevieve A Secker, Ram Seshadri, Jason A Powell, Susan J Hinze, Alison E Gardner, Hayley E Spendlove, Nathan J O'Callaghan, Anne-Marie Cleton-Jansen, Cees Cornelisse, Scott A Whitmore, Joanna Crawford, Gabriel Kremmidiotis, Grant R Sutherland, David F Callen.   

Abstract

Numerous cytogenetic and molecular studies of breast cancer have identified frequent loss of heterozygosity (LOH) of the long arm of human chromosome 16. On the basis of these data, the likely locations of breast cancer tumor suppressor genes are bands 16q22.1 and 16q24.3. We have mapped the CBFA2T3 (MTG16) gene, previously cloned as a fusion partner of the AML1 protein from a rare (16;21) leukemia translocation, to the 16q24.3 breast cancer LOH region. The expression of CBFA2T3 was significantly reduced in a number of breast cancer cell lines and in primary breast tumors, including early ductal carcinomas in situ, when compared with nontransformed breast epithelial cell lines and normal breast tissue. Reintroduction of CBFA2T3 into different breast tumor derived cell lines with decreased expression of this gene reduced colony growth on plastic and in soft agar. CBFA2T3 was shown to function as a transcriptional repressor when tethered to the GAL4 DNA-binding domain in a reporter gene assay and, therefore, has the potential to be a transcriptional repressor in normal breast epithelial cells. Taken together, these findings suggest that CBFA2T3 is a likely candidate for the breast cancer tumor suppressor gene that is the target for the frequent 16q24 LOH in breast neoplasms.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12183414

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  29 in total

1.  The enemy within: dormant retroviruses awaken.

Authors:  Michael E Engel; Scott W Hiebert
Journal:  Nat Med       Date:  2010-05       Impact factor: 53.440

Review 2.  Off to a Bad Start: Cancer Initiation by Pluripotency Regulator PRDM14.

Authors:  Lauren J Tracey; Monica J Justice
Journal:  Trends Genet       Date:  2019-05-23       Impact factor: 11.639

3.  Deletion of Mtg16, a target of t(16;21), alters hematopoietic progenitor cell proliferation and lineage allocation.

Authors:  Brenda J Chyla; Isabel Moreno-Miralles; Melissa A Steapleton; Mary Ann Thompson; Srividya Bhaskara; Michael Engel; Scott W Hiebert
Journal:  Mol Cell Biol       Date:  2008-08-18       Impact factor: 4.272

4.  Tumor suppressor SMAR1 mediates cyclin D1 repression by recruitment of the SIN3/histone deacetylase 1 complex.

Authors:  Shravanti Rampalli; L Pavithra; Altaf Bhatt; Tapas K Kundu; Samit Chattopadhyay
Journal:  Mol Cell Biol       Date:  2005-10       Impact factor: 4.272

5.  MTGR1 is required for tumorigenesis in the murine AOM/DSS colitis-associated carcinoma model.

Authors:  Caitlyn W Barrett; Barbara Fingleton; Amanda Williams; Wei Ning; Melissa A Fischer; Mary K Washington; Rupesh Chaturvedi; Keith T Wilson; Scott W Hiebert; Christopher S Williams
Journal:  Cancer Res       Date:  2011-02-08       Impact factor: 12.701

Review 6.  Runx1/AML1 in normal and abnormal hematopoiesis.

Authors:  Tetsuya Yamagata; Kazuhiro Maki; Kinuko Mitani
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

7.  Myeloid translocation gene family members associate with T-cell factors (TCFs) and influence TCF-dependent transcription.

Authors:  Amy C Moore; Joseph M Amann; Christopher S Williams; Emilios Tahinci; Tiffany E Farmer; J Andres Martinez; Genyan Yang; K Scott Luce; Ethan Lee; Scott W Hiebert
Journal:  Mol Cell Biol       Date:  2007-11-26       Impact factor: 4.272

8.  Pooled analysis of loss of heterozygosity in breast cancer: a genome scan provides comparative evidence for multiple tumor suppressors and identifies novel candidate regions.

Authors:  Brian J Miller; Daolong Wang; Ralf Krahe; Fred A Wright
Journal:  Am J Hum Genet       Date:  2003-09-16       Impact factor: 11.025

9.  The genomic landscape of 85 advanced neuroendocrine neoplasms reveals subtype-heterogeneity and potential therapeutic targets.

Authors:  Job van Riet; Harmen J G van de Werken; Edwin Cuppen; Ferry A L M Eskens; Margot Tesselaar; Linde M van Veenendaal; Heinz-Josef Klümpen; Marcus W Dercksen; Gerlof D Valk; Martijn P Lolkema; Stefan Sleijfer; Bianca Mostert
Journal:  Nat Commun       Date:  2021-07-29       Impact factor: 14.919

10.  Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling.

Authors:  A H Beck; C-H Lee; D M Witten; B C Gleason; B Edris; I Espinosa; S Zhu; R Li; K D Montgomery; R J Marinelli; R Tibshirani; T Hastie; D M Jablons; B P Rubin; C D Fletcher; R B West; M van de Rijn
Journal:  Oncogene       Date:  2009-11-09       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.